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Abstract: The incidence of obesity and colorectal cancer (CRC) has risen rapidly in recent decades.
More than 650 million obese and 2 billion overweight individuals are currently living in the world.
CRC is the third most common cancer. Obesity is regarded as one of the key environmental risk
factors for the pathogenesis of CRC. In the present review, we mainly focus on the epidemiology
of obesity and CRC in the world, the United States, and China. We also summarize the molecular
mechanisms linking obesity to CRC in different aspects, including nutriology, adipokines and
hormones, inflammation, gut microbiota, and bile acids. The unmet medical needs for obesity-related
CRC are still remarkable. Understanding the molecular basis of these associations will help develop
novel therapeutic targets and approaches for the treatment of obesity-related CRC.
Keywords: obesity; colorectal cancer; epidemiology; hormones; inflammation; gut microbiota;
bile acids
1. Introduction
Obesity is associated with various metabolic disorders [1], such as diabetes, non-alcoholic fatty
liver diseases, cardiovascular diseases, hypertension, and obstructive sleep apnea syndrome, as well
as with some cancers [2–4], including esophageal adenocarcinoma, multiple myeloma, cardia cancer,
colorectal cancer (CRC), cholangiocarcinoma, pancreatic cancer, breast cancer, endometrial cancer,
ovarian cancer, and renal cancer. Obesity is closely related to increased incidence and progression of
these cancers, and it is estimated to cause about 20% cancer-associated deaths [5,6]. In this review, we
mainly focus on the epidemiology of obesity and CRC in the world, the United States, and China, and
the molecular mechanisms of obesity contributing to CRC.
2. The Epidemiology of Obesity and CRC
2.1. The Epidemiology of Obesity
Obesity has become a worldwide health burden. Body mass index (BMI) is a typical value derived
from the weight and height to define overweight (25 ≥ BMI < 30) and obesity (BMI ≥ 30) in adult
men and women. According to the World Health Organization (WHO) reports, the rate of obesity
has nearly tripled globally since 1975. In 2016, about 2 billion adults were overweight, and more than
650 million of them were obese. The worldwide prevalence of overweight was 22.7% in women, and
20.7% in men in 1975; it was markedly increasing to 39.0% and 38.3% in 2016 and it will arrive at 49.6%
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and 51.7% in women and men respectively in 2035 (Figure 1A). The global prevalence of obesity was
6.3% for women, and 2.9% for men in 1975; this proportion rose to 15.1% (women) and 11.1% (men) in
2016 and will reach 21.6% (women) and 18.1% (men) in 2035 (Figure 1B). The regions with the highest
prevalence of obesity are American and European [7]. With an estimated 89.6 million obese, China has
the largest population of obese in the world [8]. Since 1975, the prevalence of overweight and obesity
in men and women every two decades in China and the United States is shown in Figure 1C,D. If
the current trends continue, as predicted, the prevalence of overweight and obesity in the USA will
reach 76.9% (women) and 87.1% (men), and 48.1% (women) and 46.7% (men) in 2035, respectively. The
prevalence of overweight and obesity in China will reach 43.3% (women) and 58.3% (men), and 12.8%
both in women and men in 2035, respectively. Obesity has been a serious threat to human health and a
heavy financial burden of health insurance, which affects the normal physiological function of humans.Cancers 2020, 12, x 3 of 21 
 
 
Figure 1. The prevalence of overweight and obesity in women and men. The global prevalence of 
overweight (A) and obesity (B) in women and men from 1975 to 2016 (left), and the value in 1975 and 
2016, and the prediction in 2035 (right). The prevalence of overweight (C) and obesity (D) for women 
and men in 1975, 1995, 2015, and the prediction in 2035 in China and the United States. The predicted 
values were boxed with the dashed line. Data are from the WHO website. 
2.2. The Epidemiology of Colorectal Cancer 
CRC is the third most prevalent cancer and is also the third leading cause of cancer-associated 
death globally in both men and women from the 1980s [9,10]. In 2018, there were 1.8 million new 
CRC cases, causing 0.86 million deaths worldwide, according to global cancer statistics [11]. 
Currently, there are more than 1 million CRC survivors in America. Based on American Cancer 
Society statistics 2020, the estimated numbers of new CRC cases and deaths in the United States are 
approximately 150,000 and 54,000, respectively [9]. Global Burden of Disease Study 2017 (GBD 2017) 
reported the numbers of incident cases and deaths of CRC globally, in the USA, and China from 1990 
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2.2. The Epidemiology of Colorectal Cancer
CRC is the third most prevalent cancer and is also the third leading cause of cancer-associated
death globally in both men and women from the 1980s [9,10]. In 2018, there were 1.8 million new CRC
cases, causing 0.86 million deaths worldwide, according to global cancer statistics [11]. Currently, there
are more than 1 million CRC survivors in America. Based on American Cancer Society statistics 2020,
the estimated numbers of new CRC cases and deaths in the United States are approximately 150,000
and 54,000, respectively [9]. Global Burden of Disease Study 2017 (GBD 2017) reported the numbers
of incident cases and deaths of CRC globally, in the USA, and China from 1990 to 2017, as shown in
Figure 2. We observed that in 1990, incident cases and deaths of CRC are about 107,000 and 76,000 in
China, and about 432,000 and 200,000 in 2017, respectively [12]. Over the past 27 years, the incidence
cases of CRC have doubled worldwide, and been increased three times in China. The unmet medical
needs of CRC have been a growing public health issue.
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Growing epidemiological data indicated a strong positive correlation between obesity and 
colorectal carcinogenesis [13–15]. General obesity causes a higher risk of colon cancer in males 
compared to females, and it has a stronger association with colon cancer than rectal cancer in both 
genders [16,17]. Dose-response meta-analysis reported that body weight gain of 10 kg was 
accompanied by approximately 8% increased risk of CRC [18,19]. Early-life obese individuals are at 
greater risk of developing CRC in adulthood [13,18,20]. As expected, body weight loss by bariatric 
surgery reduces about 27% risk of CRC [21,22]. Understanding the association between body weight 
and the risk of CRC is essential to guide body weight management for CRC patients. 
3. The Mechanistic Insights Linking Obesity with CRC 
Although increasing evidence suggests the positive correlation between obesity and CRC, the 
underlying molecular mechanisms are still not fully understood. Obesity-induced abnormal lipid 
metabolism, adipokines and hormones, chronic inflammation, gut microbiota dysbiosis, and 
disrupted bile acid homeostasis may play important roles in the complex metabolic regulation of 
CRC tumorigenesis. 
3.1. Nutriology 
Obesity is excess body adiposity, especially ectopic deposition of white adipose tissues. Mature 
adipocytes (white adipocytes) act as an energy bank to store and release energy [23]. Systemic and 
local energy metabolic homeostasis is primarily controlled by adipocytes [24,25]. Tumor cell growth 
requires a lot of energy. Understanding whether and how tumor cells get energy directly from the 
adipocytes helps develop new therapeutic strategies. 
Nieman et al. reported [26] that intra-abdominal tumors are more likely home to and proliferate 
in the omentum majus, which is an organ mainly composed of white adipocytes. Adipocyte-tumor 
cell coculture induces lipolysis in adipocytes and β-oxidation in tumor cells, resulting in the rapid 
proliferation of tumor cells. An emerging concept in cancer metabolism is that the adipocytes 
surrounding tumors provide energy or nutrients for the anabolic growth of cancer cells [27–29]. We 
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Growing epidemiological data indicated a strong positive correlation between obesity and
colorectal carcinogenesis [13–15]. General obesity causes a higher risk of colon cancer in males
compared to females, and it has a stronger association with colon cancer than rectal cancer in both
genders [16,17]. Dose-res onse meta-analysis reported that body weight gain of 10 kg was accompanied
by approximately 8% increased risk of CRC [18, 9]. Early-life ob se in ividuals are at g eater risk of
developing CRC in adulthood [13,18,20]. As expected, body weight loss by bariatric surgery reduces
about 27% risk of CRC [21,22]. Understanding the association between body weight and the risk of
CRC is essential to guide body weight management for CRC patients.
3. The Mechanistic Insights Linking Obesity with CRC
Although increasing vidence suggests the positive c rrelation between o e ty and CRC,
the underlying molecular echanisms are still not fully understood. Obesity-induced abnormal
lipid metabolism, adipokines and hormones, chronic inflammation, gut microbiota dysbiosis, and
disrupted bile acid homeostasis may play important roles in the complex metabolic regulation of
CRC tumorigenesis.
3.1. Nutriology
Obesity is excess body adiposity, especially ectopic deposition of white adipose tissues. Mature
adipocytes (white adipocytes) act as an energy bank to store and release energy [23]. Systemic and
local energy metabolic homeostasis is primarily controlled by adipocytes [24,25]. Tumor cell growth
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requires a lot of energy. Understanding whether and how tumor cells get energy directly from the
adipocytes helps develop new therapeutic strategies.
Nieman et al. reported [26] that intra-abdominal tumors are more likely home to and proliferate
in the omentum majus, which is an organ mainly composed of white adipocytes. Adipocyte-tumor
cell coculture induces lipolysis in adipocytes and β-oxidation in tumor cells, resulting in the rapid
proliferation of tumor cells. An emerging concept in cancer metabolism is that the adipocytes
surrounding tumors provide energy or nutrients for the anabolic growth of cancer cells [27–29]. We
validated this concept by observing more adipocytes surrounding colorectal tumor tissues than normal
tissues in clinical pathological sections [30]. In in vitro experiments, we found adipocyte-conditioned
medium promotes proliferation and migration of colon cancer cells (SW480 and C26) through retinoic
acid-related orphan α (RORα), which is a lipid metabolism-associated nuclear receptor [30]. Sadahiro
et al. reported that primary adipocytes, preadipocytes, and adipose tissues enhanced the growth
of colon cancer cells (CACO-2, T84, and HT29) in the cocultured system [31]. Adipocytes are part
of tumor microenvironment. It is domesticated to produce and transfer energy-rich metabolites to
tumor cells, including free fatty acids, glutamine, ketones, and L-lactate, and promote the growth and
migration of tumors [29]. The summarized crosstalk between CRC cells and adipocytes in nutriology
is shown in Figure 3. CRC cells domesticate adipocytes which supply energy or nutrients to cancer
cells for further rapid growth.
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Cancer cachexia (C ), als nown as wasting syndrome, is characterized by weight loss in
cancer patients. It is caused by tumor factors and regulated by catabolic metabolism [32]. This
complex multifactorial metabolic syndrome often accompanies increased lipolysis in adipose tissues.
A total of 54% of colon cancer patients suffer from CC that causes about 20% of cancer-associated
deaths [33,34]. It might be a piece of evidence that adipose tissues provide nutrients for tumor growth
in systemic nutriology.
Understanding the role of adipocytes in tumor microenvironment is critical to the discovery of
new strategies. Targeted blocking energy transfers might be novel therapies for the treatment of CRC.
3.2. Adipokines and Hormones
Adipose tissues have long been thought to be energy sto age tissues as the body accumulates
excess nutrients and to resist cold temperature [35]. It is currently regarded as a highly active endocrine
or metabolic organ [36]. It liberates more than twenty kinds of hormones and adipokines, such as
estrogens, insulin, insulin-like growth factors (IGFs), leptin, adiponectin, apelin, visfatin, resistin,
chemerin, omentin, nesfatin, vaspin, inflammatory cytokines (e.g., tumor necrosis factor-alpha (TNF-α),
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chemokine (C-C motif) ligand 2 (CCL2), plasminogen activator inhibitor-1(PAI-1), and the interleukin
families (e.g., IL-1β, IL-6, IL-8, IL-10, IL-27, and IL-31). The related adipokines and hormones and their
functions in the development and progression of CRC are introduced below.
3.2.1. Insulin and IGFs
The insulin/IGFs system is a major driver in the pathogenesis of CRC. This system consists of
insulin, insulin receptor (IR), IGF-1 and -2, IGF-1 receptor (IGF-1R), IGF-binding protein (IGFBP)-1
and -2, and IR substrates (IRS) 1 and 2 [37]. Overweight generally increases the levels of insulin and
IGF-I and decreases the levels of IGFBP-1 and IGFBP-2 in serum [38]. Insulin and IGFs have been
reported to promote the proliferation of HCT116 and HT29 colon cancer cell lines through activation
of the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway [39–41]. PI3K/Akt signal pathway
is an important therapeutic target for treating colon cancer [42,43]. Tyrosine-protein kinase Src is a
non-receptor tyrosine kinase encoded by the SRC gene in humans [44]. It regulates PI3K/Akt pathway
through phosphorylation of PI3K. Src also plays a critical role in the transformation and growth
of CRC cells. Knockdown or inhibition of Src inhibited cell metastasis and proliferation in human
cancer cells SW480 and HT29 [45,46]. Phosphorylated IR (pIR) was highly expressed in low-grade
colorectal adenocarcinoma, which indicated activation of IR is an early event in CRC tumorigenesis [47].
The expression levels of IGF1 and IGF-1R were increased in colorectal carcinomas, compared with
normal colonic mucosa. Overexpression and activation of IGF1-R can activate Src, leading to elevated
proliferation and migration of colon cancer in vitro [48]. Renehan et al. reported that IGF-2 SD
scores (SDS) were slightly increased in CRC patients compared to healthy controls, and it showed a
more dramatic increase in advanced colonic carcinomas compared with earlier stages, but the scores
dropped down immediately after curative resection [37]. Taken together, the insulin and IGFs system
plays an important role in the pathogenesis and prognosis of CRC through independent or joint
signaling networks.
3.2.2. Leptin and Adiponectin
Leptin, a peptide hormone encoded by Ob gene, is mainly secreted by adipose tissues, which
informs the brain that the energy runs out in the liver through binding to leptin receptors [49–51].
Obese individuals have high levels of circulating leptin, because of leptin resistance [52]. Leptin is a
risk factor for CRC [53,54]. The expression of leptin is increased in human colorectal tumors and is
associated with tumor progression and clinic pathological parameters [55]. Soluble leptin receptor
(sOB-R) is a potential marker of leptin resistance. European Prospective Investigation into Cancer and
Nutrition (EPIC) cohort also showed circulating sOB-R inversely correlated with the risk of CRC [56,57].
In azoxymethane (AOM) induced murine colon cancer model, Leptin-deficient (ob/ob) and leptin
receptor-deficient (db/db) mice showed inhibited tumor growth through Wnt signaling pathway [54].
Leptin increases cell proliferation and prevents apoptosis in HT29 cells through phosphorylation of
c-Jun NH2-terminal kinase (JNK). JNK phosphorylation stimulates a cascade of downstream protein
phosphorylation, including Janus kinase 2 (JAK2) and PI3K/Akt, then activates signal transducer and
activator of transcription (STAT3) and activator protein 1 (AP-1) [58]. Leptin promotes cell migration
and lamellipodial extension in human CRC cell lines LS174T and HM7 through activation of Rho
family of GTPases, including ras homolog family member A (RhoA), cell division control protein 42
(Cdc42), and ras-related C3 botulinum toxin substrate 1 (Rac1) [59]. Adipose tissues secreted leptin
inhibits mitochondrial respiration rate in HCT116 cells [60,61]. Leptin provides a link between obesity
and the risk of CRC, it is a sensitive marker of obesity-induced hormonal aberrations and may be
directly involved in CRC tumorigenesis.
Adiponectin is a protein hormone encoded by ADIPOQ gene in humans [62]. It is one of
the most abundant hormones released from adipose tissues and performs an essential function in
obesity-associated cancers. The expression and circulating levels of adiponectin are reduced in most
obese individuals and animal models of obesity [63–65]. Epidemiology studies showed that decreased
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plasma adiponectin levels are inversely correlated with the risk of colon cancer [66,67]. Adiponectin
knockout (APNKO) mice exhibited more tumor numbers and areas in dextran sodium sulfate (DSS)
and 1,2-dimethylhydrazine (DMH) induced colon cancer model through increasing the differentiation
from epithelial cells to goblet cells and inhibiting goblet cell apoptosis. It indicated that adiponectin
protected against chronic inflammation-induced colon cancer [68]. High-fat diet treated mice had
more and larger colorectal tumors than chow-diet mice. Adiponectin administration decreased tumor
growth through inhibiting angiogenesis [69,70]. In vitro experiments, adiponectin inhibits colon
cancer cell growth in adiponectin receptor (AdipoR1- and -R2) positive HCT116, HT29, and LoVo cells
through the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) signaling
pathway [71,72]. Moon et al. demonstrated that adiponectin directly regulated cell proliferation,
migration, adhesion, and colon formation through regulation of metabolism, inflammation, and cell
cycle in MCA38, HT29, HCT116, and LoVo cells [69]. These results indicate the potential inhibitory
effect of adiponectin on the development of CRC. Together, leptin and adiponectin generally show
opposite molecular effects on obesity and cellular behaviors. They are relevant but reverse players in
obesity-related CRC.
3.2.3. Estrogens
It is well established that estrogen contributes to obesity-associated hormone-responsive cancers,
especially breast cancer [73,74]. The role of estrogen in obesity-associated CRC is complicated. First,
estrogens have been found to reduce the risk of CRC [75]. Hormone replacement therapy confers
protection against CRC, especially for lean women, as indicated by epidemiological data [76]. Estrogen
replacement therapy in postmenopausal women reduces CRC-related mortality [77]. These cohort
studies indicated estrogens may play a protective role in the pathogenesis of CRC. Interestingly, adipose
tissues are also partial source of estrogen in addition to ovaries. Plasma estrogen levels are increased
in obese men and postmenopausal women, because adipose tissue aromatase transforms androgenic
precursors to estrogens [78]. However, several studies have shown that high BMI increased the risk
of CRC in men and premenopausal women, but not postmenopausal women [79,80]. Adiposity also
positively correlates with blood insulin, leading to increased IGF-1. The inducible effect of insulin/IGF-1
axis on CRC appears to be compromised by estrogen released from adiposity in postmenopausal
women. In premenopausal women, the primary source of estrogen is ovary compared to adiposity.
Thus, more hormone supplement cannot provide more benefits [79,81]. This concept has been suggested
by several cohort studies showing a positive correlation between BMI and CRC risk in younger women
(<55-year-old) but not in older women [79,80,82]. This association was further confirmed by the study
subjected between BMI and CRC risk in premenopausal and postmenopausal women. The risk of CRC
in postmenopausal women is independent of BMI [83]. Although the relationship among hormones,
obesity, and CRC is not fully understood, these observations and reasonable speculation emphasize
the same importance of weight control in both genders.
The effect of estrogen is mediated by its receptors, estrogen receptor (ER)-α and ER-β. The
expression of ER-α is very low in normal colorectal tissues. However, the ER-α expression is increased
with the development of colon cancer, and it positively correlates with CRC stages and worse
survival [75]. ER-β is enriched in colon tissues [84]. The expression of ER-β is lower in colon tumor
tissues compared with normal tissues and inversely correlates with the progression of CRC [85,86].
ER-β overexpression induced cell-cycle arrest and inhibited cell proliferation and tumor growth in
SW480 cells and mouse xenografts model [87]. In the ApcMin/+ mouse model, estrogen treatment
protected against CRC and increased the ratio of ER-β to ER-α [88]. Ablation of ER-β in ApcMin/+
mice significantly increased tumor formation, and treatment with estrogen could not prevent this
phenotype [89]. These results indicate that ER-β is responsible for the protective effect of estrogens on
colon tumorigenesis.
We summarize the signaling pathways of obesity-secreted adipokines and hormones in the
pathogenesis of CRC (Figure 4).
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3.3. Inflammation
Obesity, as a characteristic of metabolic syndrome, is related to chronic low-grade inflammation in
obese subjects, because of various pro- and anti-inflammatory cytokines produced by adipose tissues,
including IL-6, TNF-α, CCL2, PAI-1, a d others [90,91]. Chronic inflammation is a major link between
obesity and tumor microenvironment in CRC.
Obesity is associated with circulating levels of IL-6. It has been reported that about 30% of
circulating IL-6 was secreted from adipose tissues [91,92]. Circulating IL-6 is an important inflammatory
factor in the acute inflammatory reaction which sti ulates C-reactive protein (CRP) synthesis and
secretion in the l ver [91]. IL-6 is found in the tumor micro nvironment of both murine and human colon
cancer [93,94]. Prediagnostic plasma CRP, a general marker for inflammation, is also a reliable biomarker
for CRC clinically [95]. Elevated levels of circulating CRP or IL-6 in CRC patients were associated with
cancer progression, relapse, and worse survival [96,97]. IL-6 may act as a CRC-promoting cytokine
due to its inflammatory property.
TNF-α is also secreted from adipose tissues. TNF-α expression in adipose tissues is positively
correlated with the degree of obesity and associated type 2 diabetes mellitus(T2DM) [98,99]. The
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production of TNF-α is elevated in IBD patients and it is involved in the pathogenesis of IBD and
associated CRC [100–102]. TNF-α can stimulate NF-κB activation, and the activation of IKK/NF-κB
pathway is indispensable for colitis and colorectal carcinogenesis [103,104]. TNF-α promoted the
proliferation and migration of CD44+CD133+ HT29 cells by activation of Wnt/β-catenin signaling
pathway [101]. Treatment with low concentrations of TNF-α (20 µg/L) enhanced cell migration and
invasion in HCT116 cells through upregulating tumor-associated calcium signal transduction protein 2
(TROP-2) by phosphorylation of extracellular signal-regulated kinase (ERK)1/2 signaling pathway [105].
CCL2, also known as monocyte chemoattractant protein 1 (MCP-1), is secreted by adipocytes and
plays a crucial role in inflammatory reaction [106]. Circulating levels of pro-inflammatory CCL2 is also
increased in obese subjects [107]. Tumor-associated macrophage induced inflammation is related to poor
prognosis of CRC. CCL2 is an imperative monocyte-attracting chemokine stimulating the recruitment
of macrophages into the sites of tumors [108]. Knockout CCL2 in ApcMin/+ mice (ApcMin/+/CCL2−/−)
inhibited tumor growth and immune infiltration in colon cancer [109]. CCL2 facilitated the
accumulation of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) into the tumor
microenvironment and increased MDSC-mediated inhibition of T cells in a STAT3-dependent manner,
and blocking CCL2 using antibodies reduced tumor growth and MDSC infiltration in a murine model
of colitis-associated CRC [109]. Targeting inhibition of CCL2 may provide therapeutic benefits for the
prevention and interception of CRC.
PAI-1 is encoded by SERPINE1 gene in humans. It is secreted mainly by hepatocytes and
endothelial cells, and partly by adipose tissues [110]. Clinically, PAI-1 expression in various tumors is
higher than that in normal tissues [111]. The plasma PAI-1 level was increased in CRC patients, but
it was not correlated with the risk of colonic carcinogenesis [112]. Recently, Gerard reported [113]
that PAI-1 aggravated mucosal damage through PAI1–tPA axis and activation of transforming growth
factor β (TGF-β) in human and murine colitis. Knockout PAI-1 or treatment with PAI-1 inhibitor
reduced inflammation and mucosal damage in DSS- and Citrobacter-induced colitis [114]. PAI-1 is an
important inducer of the inflammatory reaction in colonic epithelial cells.
Low-grade chronic inflammation is a main feature of obesity, it mediates most of the obesity-related
complications [115]. Inflammation also plays an important role in the tumor microenvironment of
CRC to activate the signaling of proliferation, migration, and metastasis [116,117]. Therefore, obesity
triggered chronic subclinical inflammation is a bridge linking obesity to colorectal carcinogenesis. We
summarize the mechanisms by which obesity-induced chronic inflammation leads to the carcinogenesis
of CRC (Figure 5).
3.4. Gut Microbiota
Gut microbiota has become increasingly important for health with the launch of the National
Microbiome Initiative and Human Microbiome Project in America in recent years [118,119]. In humans,
about 1.5 kg microbes reside in the gut and make up half of the fecal matter biomass [120]. Increasing
evidence indicated that gut microbiota is considered as a potential factor in the pathogenesis of obesity
and associated metabolic disorders, even cancers [121–123]. Understanding the role of gut microbiome
in obese and CRC individuals will provide potential molecular insights and therapeutic targets to
prevent or treat both diseases.
Germ-free animals are critical for studying the effect of microbes on host physiological and
pathological processes. In different high fat and carbohydrate diets induced obesity models, germ-free
animals have more food intake but gain less body weight compared with the conventional controls [122].
In carcinogen-induced and spontaneous colon cancer models, germ-free animals also show inhibited
tumorigenesis in most cases [124]. Vannucci et al. reported that germ-free rats exhibited reduced
tumor formation and enhanced anti-cancer immune response in AOM-induced CRC compared with
conventional conditions [125]. T-cell receptor β chain and p53 double-knockout (TCRβ−/−, p53−/−) mice
can spontaneously form colorectal tumors. The rate of tumor formation is about 70% in conventional
mice. Whereas, there is almost no tumor in the germ-free mice [126]. Tomkovich et al. found that
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germ-free ApcMin/+ and IL10−/− mice had less colorectal tumors compared to specific-pathogen-free
and gnotobiotic controls, and polyketide synthase (pks)+ Escherichia coli promoted carcinogenesis
mediated by colibactin [127].
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Lipopolysaccharide (LPS) is an endotoxin produced by gram-negative bacteria in the gut and
is associated with l w-grade chronic inflammation [128]. Circulating LPS was elevated i high-fat
diet (HFD) induced obesity due to a gut microbiome remodeling [129,130]. We recently found
HFD increased the abundance of LPS-producing pathogens Desulfovibrio in mice [129]. Bacteria and
endotoxins are prevented by intestinal mucosal barrier [131]. Increased intestinal permeability and
systemic endotoxemia aggravated colitis and associate CRC. Bacteria secreted LPS directly exacerbates
extracellular m trix adhesion and invasion in SW480, SW620, and CACO2 cells through activation
of the urokinase plasminogen activator (u-PA) system in a TLR-4/NF-κB dependent manner [132].
Wenting et al. found that LPS increased the migration and invasion of colorectal cancer cells in vivo
and in vitro by promoting epithelial-mesenchymal transition (EMT) and activation of SDF-1α/CXCR4/
NF-κB axis [133]. LPS participates in the enhancement of CRC malignant behaviors, and it may serve
as a biomarker for CRC metastasis.
Gut mi robiota can produce some be eficial m tabolites, such s short-chained fatty acids
(SCFAs). SCFAs are key mediators linking diet and gut microbiota to prevent obesity and related
metabolic disorders [134,135]. SCFAs are the major source of energy for colonocytes, and important
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for gastrointestinal health to maintain intestinal barrier function [136]. SCFAs also play a beneficial
role in CRC clinically [137]. Mechanically, SCFAs inhibited cell growth and differentiation, promoted
cell-cycle arrest and apoptosis, and regulated histone acetylation to protect against CRC [138]. Given
the potential benefits of SCFAs, they are also considered as useful probiotics to prevent CRC.
Akkermansia muciniphila, a genus of the phylum Verrucomicrobia, is a probiotic for preventing both
obesity and CRC [139–142]. The Patrice group found Akkermansia protected against HFD-induced
obesity through increasing intestinal endocannabinoids that reduced inflammation and enhanced gut
barrier function [143]. Further, they found Amuc_1100, a specific membrane protein purified from
Akkermansia, improved metabolic syndrome in obese and diabetic mice through TLR2 signaling [144].
In obese human volunteers, Akkermansia administration improved insulin sensitivity and inflammation,
mildly reduced body weight, compared to placebo [145]. Akkermansia is also a crucial player in
gastrointestinal disorders. Treatment with Akkermansia inhibited DSS-induced colitis in mice [146].
Amuc_1100 and pasteurized Akkermansia blunted colitis and associated CRC tumorigenesis through
regulation of macrophages and CD8+ cytotoxic T lymphocytes in mouse colon [147]. Lactobacillus casei
is a genus of Lactobacillus. Oral administration of Lactobacillus casei enhanced CD8+ T cell infiltration
and inhibited colon carcinoma growth in tumor-bearing mice [148]. These data indicate that potential
probiotic bacteria and beneficial metabolites are promising therapeutic agents for treating obesity
and CRC.
3.5. Bile Acids
Bile acids (BAs), amphipathic molecules, mainly mediate intestinal dietary fat absorption. The
primary BAs are synthesized from cholesterol in the liver and secreted into the intestine where
pancreatic lipase is activated to form micelles and promotes nutrient absorption [149]. BAs also serve
as signaling molecules to regulate farnesoid X receptor (FXR) and G protein-coupled receptor (GPCR)
signaling, thereby maintaining energy and metabolic homeostasis [150]. BAs play key roles in lipid
metabolism. The synthesis of BAs is associated with circulating triglyceride levels in patients with
hyperlipoidemia [151]. Cholestyramine is a BA sequestrant commonly used for reducing high serum
cholesterol levels in patients [152]. In the obesity models, total BAs were slightly increased, while
conjugated BAs and deoxycholic acid (DCA) were dramatically elevated in plasma and liver [153,154].
The level of total BAs is correlated with BMI in obese patients [149]. BAs, especially secondary BAs,
are potent carcinogens or promoters for CRC. Numerous studies reported that BAs are strong inducers
for CRC tumorigenesis by damaging colonic epithelium, stimulating inflammatory reactions [155],
inducing reactive oxygen species (ROS) production [156], promoting genomic instability, and resisting
apoptosis [157]. Targeting BAs might be an effective strategy for the prevention and treatment of CRC.
FXR is a bile acid receptor (BAR), encoded by the NR1H4 gene and highly expressed in the
liver and intestine tissues [158]. FXR is a double-edged sword in obesity. Evans et al. reported
activation of intestinal FXR by fexaramine inhibited obesity and increased adipose tissue browning
through fibroblast growth factor 15 (FGF15) signaling [159,160]. On the other hand, Frank et al.
found Glycine-β-muricholic acid (Gly-MCA), an intestine-specific FXR inhibitor, reduced obesity and
associated metabolic dysfunction through inhibition of ceramide metabolism [161]. Additionally, FXR
is a therapeutic target to protect against colorectal tumorigenesis. FXR inhibited colonic tumor growth
in vivo. Knockout FXR in the ApcMin/+ mice promoted tumor progression and accelerated mortality
through activation of Wnt/β-catenin signaling pathway [158,162]. T-β-MCA, a known FXR antagonist,
was reported to promote CRC progression in HFD-induced APCmin/+ mice through damaging DNA
and increasing proliferation in leucine-rich repeat-containing G protein-coupled receptor 5 positive
(LGR5+) cancer stem cells [163]. Given the anti-tumor activity, intestinal FXR has promising therapeutic
value in treating CRC.
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4. Conclusions
Both obesity and CRC are global health burdens currently. Epidemiologic data indicate a positive
correlation between obesity and CRC. Obesity plays a direct and independent role in colorectal
carcinogenesis. In the present review, we described the epidemiology of obesity and CRC respectively,
and then summarized the potential underlying mechanisms linking obesity to CRC in different aspects,
including nutriology, adipokines and hormones, inflammation, gut microbiota, and bile acids as shown
in Figure 6. In nurtiology, adipocytes in tumor microenvironment are an energy source for CRC growth.
In adipose tissue secreted adipokines and inflammation, elevated levels of insulin, IGFs, leptin, and
inflammatory cytokines (e.g., IL-6, TNF-α, CCL2, and PAI-1), and decreased levels of adiponectin in
obese, which alone or together contribute to the formation and development of CRC. Interestingly,
circulating estrogen level is increased in obese individuals. It is known that estrogen contributes to
obesity related breast cancer, but the role of estrogen in obesity-associated CRC is controversial. Cohort
studies showed that BMI affects males stronger than females in the carcinogenesis of CRC, indicating
estrogen may have a protective effect in CRC. In gut microbiota, obesity induced gut microbiota
dysbiosis increases harmful microbiota and metabolites (LPS) and decreases beneficial microbiota
(Akkermansia) and metabolites (SCFAs), which might lead to CRC tumorigenesis. In bile acids, bile
acids promote CRC progression, especially DCA and T-β-MCA which are increased in obesity. The
carcinogenesis of CRC is promoted by the bile acid-dependent inhibition of FXR, which is a target for
anti-CRC. Therefore, obesity induces complex biological activities to promote CRC tumorigenesis.
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Besides obesity, epidemiologic evidence showed dietary and lifestyle factors include red/processed
meat diet, low-fiber and high-fa diet, alc hol drinking, smoking, sedentary, and low phy ical activity are
important environmental factors for CRC risk [164]. Ge etic risk factors include familial adenomatous
polyposis (FAP), and certain genetic mutations [165] (e.g., mutL homolog 1 (MLH1), adenomatous
polyposis coli (APC), K-Ras (KRAS), and tumor protein p53 (TP53) genes). Environmental and genetic
factors commonly contribute to CRC development. Reducing weight, improving diet, decreasing
alcohol intake and smoking, d in addition t reducing sedentary time and incr asi physic l activity
are likely to improve CRC incidence and mort lity.
In summary, we mainly focus on the role of obesity in CRC. The potential underlying biological
mechanisms linking obesity to CRC are warranted, although great strides have been made to understand
the biological mechanisms in obesity and the pathogenesis of CRC, respectively. Obesity induces
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insulin, IGFs, leptin, IL-6, TNF-α, CCL2, and PAI-1, reduces adiponectin, and disturbs gut microbiota
and bile acid homeostasis. These altered factors promote CRC carcinogenesis mediated by downstream
signaling pathways. Our increased understanding of the link between obesity risk factors and CRC
carcinogenic processes will help to uncover more promising therapeutic targets and approaches for
obesity-related CRC treatment in the future.
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